Perspective Therapeutics, Inc. Common Stock — Cash Flow (NYSE:CATX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -2.84 M-7.71 M-36.91 M-18.29 M-82.48 M -92.37 M Cash from investing activities -410 K-284 K24.37 M-218.93 M41.23 M -62.76 M Cash from financing activities 64.68 M56 K785 K289.38 M10.3 M 164.7 M Free cash flow -2.84 M-7.71 M-36.91 M-18.29 M-82.48 M -92.37 M

News

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst Call - Slideshow (NYSE:CATX) 2026-05-04

Perspective Therapeutics - Decent Prospect In Radiopharmaceuticals Field (NYSE:CATX)

Truist reiterates Buy on Perspective Therapeutics stock

RBC cuts Perspective Therapeutics stock price target on model updates

Perspective Therapeutics stock rating reiterated at Buy by BTIG

Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform

Perspective Therapeutics earnings missed by $0.16, revenue fell short of estimates

Piper Sandler initiates Perspective Therapeutics stock rating at overweight

Perspective Therapeutics shares rise after $175 million offering

Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright

Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript